A
834.55
1.39 (0.17%)
| Penutupan Terdahulu | 833.16 |
| Buka | 832.15 |
| Jumlah Dagangan | 197,028 |
| Purata Dagangan (3B) | 358,860 |
| Modal Pasaran | 51,644,796,928 |
| Harga / Pendapatan (P/E TTM) | 35.71 |
| Harga / Pendapatan (P/E Ke hadapan) | 27.47 |
| Harga / Jualan (P/S) | 14.83 |
| Harga / Buku (P/B) | 8.24 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Keuntungan | 40.26% |
| Margin Operasi (TTM) | 17.50% |
| EPS Cair (TTM) | 16.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 95.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.71% |
| Nisbah Semasa (MRQ) | 7.29 |
| Aliran Tunai Operasi (OCF TTM) | -82.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -143.39 M |
| Pulangan Atas Aset (ROA TTM) | -0.21% |
| Pulangan Atas Ekuiti (ROE TTM) | 17.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | argenx SE | Menaik | Menaik |
AISkor Stockmoo
1.5
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.5 |
| Purata | 1.50 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Institusi | 55.54% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 1,317.00 (Wells Fargo, 57.81%) | Beli |
| Median | 1,091.00 (30.73%) | |
| Rendah | 858.00 (Baird, 2.81%) | Pegang |
| Purata | 1,075.44 (28.87%) | |
| Jumlah | 8 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 846.16 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 20 Jan 2026 | 1,317.00 (57.81%) | Beli | 809.64 |
| 16 Dec 2025 | 1,264.00 (51.46%) | Beli | 851.42 | |
| Wedbush | 14 Jan 2026 | 1,000.00 (19.83%) | Beli | 799.33 |
| 14 Nov 2025 | 1,000.00 (19.83%) | Beli | 907.98 | |
| Citigroup | 08 Jan 2026 | 1,091.00 (30.73%) | Beli | 795.57 |
| 17 Nov 2025 | 1,124.00 (34.68%) | Beli | 929.61 | |
| Truist Securities | 08 Jan 2026 | 1,030.00 (23.42%) | Beli | 795.57 |
| Baird | 18 Dec 2025 | 858.00 (2.81%) | Pegang | 847.05 |
| RBC Capital | 17 Dec 2025 | 925.00 (10.84%) | Beli | 862.05 |
| Stifel | 11 Dec 2025 | 1,248.00 (49.54%) | Beli | 889.49 |
| JP Morgan | 08 Dec 2025 | 1,100.00 (31.81%) | Beli | 900.76 |
| Morgan Stanley | 04 Dec 2025 | 1,110.00 (33.01%) | Beli | 915.97 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2026 | Pengumuman | argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG |
| 12 Jan 2026 | Pengumuman | argenx Highlights 2026 Strategic Priorities |
| 06 Jan 2026 | Pengumuman | argenx to Present at 44th Annual J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Pengumuman | argenx Announces Leadership Transition Marking Next Evolution of Growth |
| 15 Dec 2025 | Pengumuman | argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease |
| 18 Nov 2025 | Pengumuman | argenx Announces Results of Extraordinary General Meeting of Shareholders |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |